NA-Semax-Amidate
A chemically modified version of Semax designed for improved stability. No published clinical or preclinical data exists for this specific compound.
What is NA-Semax-Amidate?
NA-Semax-Amidate is a modified version of Semax with N-acetyl and C-amide modifications designed to enhance stability against enzymatic degradation. There are no published clinical or preclinical studies on this specific compound. All evidence for its effects is extrapolated from research on the parent compound Semax, which is a synthetic analog of ACTH(4-10) extensively studied in Russia for cognitive enhancement, neuroprotection in ischemic stroke, BDNF upregulation, antistress effects, and immune modulation.
What NA-Semax-Amidate Is Investigated For
NA-Semax-Amidate is a chemically modified version of Semax promoted for the same range of cognitive-enhancement, neuroprotection, BDNF/NGF upregulation, and antistress applications as the parent compound. The critical fact is that zero published clinical or preclinical studies have tested NA-Semax-Amidate itself — every efficacy claim is extrapolation from the Semax literature plus a chemistry assumption that N-acetylation and C-amidation produce a longer-lasting Semax-like effect. The parent Semax has moderate Russian clinical evidence for ischemic stroke and is registered as a medicine there, but that approval does not transfer to the modified compound, and the stability advantage itself has never been demonstrated in comparative human pharmacokinetics. A user of this peptide is making three layered assumptions — that the Semax literature applies, that the modifications behave as advertised, and that the specific research-chemical product is what it claims to be — none of which is verified.
History & Discovery
NA-Semax-Amidate is not a peptide with a discovery story in the academic sense — it is a chemical modification of Semax produced and sold primarily through research-chemical channels rather than developed through a pharmaceutical research program. The two modifications — N-terminal acetylation and C-terminal amidation — are standard medicinal-chemistry techniques applied to short peptides to extend half-life by protecting against the aminopeptidases and carboxypeptidases that would otherwise rapidly degrade the molecule. Both modifications reduce the peptide's susceptibility to enzymatic clipping at its termini. The parent compound Semax was developed at the Institute of Molecular Genetics of the Russian Academy of Sciences in the 1980s, where Nikolai Myasoedov and colleagues designed a heptapeptide corresponding to the 4–10 region of ACTH with a proline-glycine-proline tail to resist proteolysis. Semax was registered as a medicine in Russia and remains in clinical use there for cognitive impairment and stroke recovery. NA-Semax-Amidate adds further chemical protection to the Semax scaffold but, unlike Semax itself, has not been the subject of an academic clinical-development program. The compound emerged in research-chemical and nootropic markets in the mid-2010s, sold on the implicit claim that the additional modifications produce an enhanced or longer-lasting Semax-like effect. The critical fact about NA-Semax-Amidate is that this implicit claim is not supported by published comparative pharmacology in humans or animals. There are no head-to-head studies of NA-Semax-Amidate versus Semax for either pharmacokinetics or behavioral or clinical effect. What exists is an extensive Semax literature and a chemistry intuition about what acetylation and amidation should do — but no validation that those modifications, applied to this specific peptide, produce the claimed outcome.
How It Works
NA-Semax-Amidate is assumed to work through the same pathways as Semax, which has been shown in rodent studies to activate dopaminergic and serotonergic systems, upregulate BDNF and NGF expression, and modulate neuroinflammatory gene expression. The N-acetyl and amide modifications are intended to improve stability, but their effect on biological activity has not been directly studied.
The N-acetylation is designed to protect against aminopeptidase degradation while the C-terminal amidation increases resistance to carboxypeptidases. One study shows N-acetylation alters copper(II) and zinc(II) coordination properties of the Semax peptide. Semax itself has demonstrated high affinity for copper(II) ions and can reduce Cu(II)-catalyzed ROS production and amyloid-beta toxicity through metal ion stripping and redox silencing. The parent compound activates transcription of BDNF, NGF, and their receptors in hippocampus, frontal cortex, and retina, with effects detectable within hours of administration. Semax also modulates immune gene expression in post-stroke brain tissue and targets the mu opioid receptor gene Oprm1 in spinal cord injury models. These mechanisms have not been verified for the NA-Semax-Amidate form.
Evidence Snapshot
Human Clinical Evidence
None for NA-Semax-Amidate specifically. The parent compound Semax has been studied in Russian clinical trials for ischemic stroke and has shown effects on brain default mode network connectivity in healthy volunteers.
Animal / Preclinical
None specific to this compound. The parent compound Semax has extensive preclinical data showing BDNF/NGF upregulation, neuroprotection in ischemia-reperfusion models, antidepressant-like effects, immune modulation under stress, and copper-chelating properties that reduce amyloid-beta toxicity.
Mechanistic Rationale
Based on well-understood peptide modification principles applied to the Semax scaffold. N-acetylation and C-amidation are standard approaches to improve enzymatic stability, but the specific pharmacological consequences for NA-Semax-Amidate have not been verified.
Research Gaps & Open Questions
What the current literature has not yet settled about NA-Semax-Amidate:
- 01Any human clinical trial for NA-Semax-Amidate specifically — no published Phase I, II, or III study has tested this compound in humans for safety, pharmacokinetics, or efficacy.
- 02Comparative pharmacokinetics versus standard Semax — the central premise of NA-Semax-Amidate (longer half-life, higher exposure, extended duration of action) has not been demonstrated in published comparative studies in any species.
- 03Comparative behavioral or clinical effects versus standard Semax — no head-to-head data exist for any endpoint.
- 04Stability and storage characteristics — the modifications are intended to improve enzymatic stability in vivo, but stability in storage and during shipment through research-chemical supply chains is uncharacterized.
- 05Effect of modifications on receptor and target engagement — Semax's effects involve dopaminergic, serotonergic, BDNF/NGF, and immune-gene modulation; whether the chemical modifications preserve, enhance, or diminish each of these effects is not characterized.
- 06Long-term safety — no chronic-use data for NA-Semax-Amidate at any time scale.
Forms & Administration
Administered intranasally, similar to Semax. No published dosing data exists for this specific compound. Protocols should be determined by a qualified clinician.
Dosing & Protocols
The ranges below reflect protocols commonly discussed in the literature and by clinicians — not a prescription. Actual dosing for any individual should be determined by a qualified healthcare provider who knows the patient.
Typical Range
There is no validated dose range for NA-Semax-Amidate. Forum-described intranasal protocols typically cite 100–600 µg per dose, often based on Semax dosing extrapolated downward on the assumption that the modifications produce a longer-acting compound that requires less frequent administration. There is no pharmacokinetic basis for any specific number.
Frequency
Forum-described protocols typically use once-daily or twice-daily intranasal dosing, in contrast to the 2–3 daily doses commonly used with standard Semax. The reduced frequency is justified by the assumption — not the demonstration — that the chemical modifications extend the duration of action.
Timing Considerations
No specific timing requirements: can be administered at any time of day, with or without food, and is not tied to exercise timing. Consistency matters more than the specific clock — dose at roughly the same time each day (or same day each week, for weekly protocols) to keep exposure steady.
Cycle Length
No clinical or research basis exists for a specific cycle length. Forum protocols commonly describe 2–4 week courses, mirroring Semax conventions for cognitive use, with a break between courses. This pattern is convention, not evidence.
Protocol Notes
Practical considerations are dominated by the absence of validation. The compound is sold by research-chemical suppliers with no chain-of-custody, no third-party potency testing, and no characterization of stability in storage. Two vials labeled 'NA-Semax-Amidate' from different sources are not necessarily the same compound at the same concentration. Intranasal delivery is the standard route, mirroring Semax. Practical administration is the same: a few drops per nostril from a dropper bottle, head tilted back, gentle sniff. Nasal irritation considerations are also similar to Semax. The most honest framing of NA-Semax-Amidate is that any user is making three layered assumptions: (1) the Semax literature applies meaningfully to this modified compound; (2) the modifications produce the claimed pharmacokinetic improvement; and (3) the specific product purchased is what it claims to be. None of these assumptions is verified, and the cumulative uncertainty is substantial.
NA-Semax-Amidate has never been tested in humans in a published clinical trial and is not approved for any indication anywhere. Standard Semax is approved as a medicine in Russia under that national framework, but NA-Semax-Amidate is not an approved formulation of Semax and the Russian regulatory approval does not extend to it.
Timeline of Effects
Onset
No published pharmacokinetic data exist for NA-Semax-Amidate. By extrapolation from Semax (subjective onset typically reported within 15–60 minutes of intranasal dosing), users typically describe similar onset, though without verification.
Peak Effect
By extrapolation from Semax, peak subjective effects are typically described in the 1–3 hour window after an intranasal dose. The premise of the modifications is that peak effects might be either higher or longer-lasting than with standard Semax — but neither has been demonstrated comparatively.
After Discontinuation
No data. Acute effects would be expected to fade within hours of clearance, similar to Semax. Whether the modified compound produces different downstream signaling persistence than the parent has not been studied.
Common Questions
Who NA-Semax-Amidate Is NOT For
- •Pregnancy — no human pregnancy data; the parent Semax label lists pregnancy as a contraindication and the same precaution applies here.
- •Breastfeeding — no data on milk transfer or infant exposure.
- •Pediatric use — no pediatric safety data for NA-Semax-Amidate; the parent Semax has specific Russian pediatric registrations that do not extend to this modified compound.
- •Acute psychotic disorders — Semax's modulation of dopaminergic and serotonergic systems leads to general avoidance in active psychosis, and the same precaution applies to a modified analog with theoretically extended duration.
- •Severe nasal mucosal disease, chronic rhinitis, or recent nasal surgery — intranasal delivery may be poorly tolerated or disrupted.
- •Known hypersensitivity to peptide therapeutics or to research-chemical excipients of unverified composition.
Drug & Supplement Interactions
There are no published clinical drug-interaction studies for NA-Semax-Amidate. By mechanistic inference from Semax, the most plausible theoretical interactions involve other CNS-active agents — particularly serotonergic drugs (SSRIs, SNRIs, MAOIs, triptans) and strong dopaminergic agents (stimulants, dopamine agonists), where co-administration could shift the pharmacologic balance. The theoretical concern is somewhat amplified for NA-Semax-Amidate compared to standard Semax, because the modifications are intended to extend duration of action. If the modifications work as advertised, the window of any pharmacodynamic interaction would be longer, which means the practical importance of avoiding co-administration with other CNS-active agents is higher rather than lower. No specific concerns are documented with cardiovascular, metabolic, or endocrine medications. Patients on any regular medication should disclose use to their prescriber, but the responsible answer in most cases is that an unstudied research-chemical compound is not appropriate to combine with prescribed medication outside a controlled research setting.
Safety Profile
Common Side Effects
Cautions
- • No published safety data for this specific compound
- • Not approved in any jurisdiction
- • All safety assumptions are extrapolated from Semax
What We Don't Know
The safety profile of NA-Semax-Amidate has not been characterized in any published study. It is unknown whether the chemical modifications alter the safety profile relative to Semax.
Legal Status
United States
NA-Semax-Amidate is not FDA-approved for any indication. It has never been the subject of a published human clinical trial. It is not a controlled substance, not a recognized dietary supplement ingredient, and not legitimately compounded as a medication. Sale is essentially limited to research-chemical channels not authorized for human use.
International
Standard Semax is approved as a medicine in Russia and several CIS countries. NA-Semax-Amidate is not an approved variant of Semax in those jurisdictions and is not approved as a medicine anywhere. EMA, MHRA, TGA, and Health Canada do not recognize it. Importation through research-chemical channels is restricted in jurisdictions that police peptide trade actively.
Sports & Competition
NA-Semax-Amidate is not currently named on the WADA Prohibited List. WADA's S0 'non-approved substances' clause arguably applies — and applies more cleanly to NA-Semax-Amidate than to standard Semax, since NA-Semax-Amidate has no regulatory approval anywhere. Athletes subject to WADA, USADA, or equivalent bodies should treat it as prohibited absent specific guidance.
Regulatory status changes over time. Verify current local rules with a qualified professional.
Myths & Misconceptions
Myth
NA-Semax-Amidate is a stronger or longer-acting version of Semax that has been validated in research.
Reality
The chemical modifications are intended to improve metabolic stability based on standard medicinal chemistry principles, but the actual pharmacokinetic improvement, behavioral effect, and clinical effect of NA-Semax-Amidate compared to Semax have not been demonstrated in any published comparative study. The 'enhanced' positioning is marketing inference, not data.
Myth
Because Semax is approved in Russia, NA-Semax-Amidate inherits that regulatory legitimacy.
Reality
Russian regulatory approval applies specifically to the Semax formulation manufactured by Geropharm and other registered Russian producers. NA-Semax-Amidate is a chemically different compound and is not an approved variant of Semax in Russia or anywhere else. The regulatory approval does not transfer.
Myth
The Semax research literature applies directly to NA-Semax-Amidate.
Reality
It applies as a mechanistic starting point, not as direct evidence. The Semax literature documents effects of the parent compound. Whether the chemical modifications change those effects — qualitatively or quantitatively — has not been studied. Inferring NA-Semax-Amidate's behavioral or safety profile from Semax studies is reasonable as a hypothesis but not as evidence.
Myth
Research-chemical NA-Semax-Amidate is reliably the molecule it claims to be.
Reality
Research-chemical channels offer no chain-of-custody, no third-party identity confirmation, and no potency testing. Identity, purity, and concentration are unverified. Mislabeling, substitution with cheaper peptides, and degradation in transit are real possibilities. Even motivated buyers cannot reliably verify what they are receiving.
Myth
If standard Semax has a long safety record, NA-Semax-Amidate must be similarly safe.
Reality
Standard Semax has a multi-decade Russian clinical record at specific doses for specific indications. That safety record reflects exposure to a specific molecular entity at controlled doses. Chemical modifications can shift biodistribution, target engagement, off-target effects, and immunogenicity in ways that the parent compound's safety record does not predict. The cautious framing is that NA-Semax-Amidate has its own safety profile that has not been characterized.
Published Research
18 studiesThe potential of the peptide drug Semax and its derivative for correcting pathological impairments in the animal model of Alzheimer's disease
Semax peptide targets the mu opioid receptor gene Oprm1 to promote deubiquitination and functional recovery after spinal cord injury in female mice
Semax, a copper chelator peptide, decreases the Cu(II)-catalyzed ROS production and cytotoxicity of Abeta by metal ion stripping and redox silencing
Antidepressant-like and antistress effects of the ACTH(4-10) synthetic analogs Semax and Melanotan II on male rats in a model of chronic unpredictable stress
Brain protein expression profile confirms the protective effect of the ACTH(4-7)PGP peptide (Semax) in a rat model of cerebral ischemia-reperfusion
Semax, synthetic ACTH(4-10) analogue, attenuates behavioural and neurochemical alterations following early-life fluvoxamine exposure in white rats
Novel insights into the protective properties of ACTH(4-7)PGP (Semax) peptide at the transcriptome level following cerebral ischaemia-reperfusion in rats
Experimental substantiation of application of Semax as a modulator of immune reaction on the model of social stress
Effects of Semax on the default mode network of the brain
The efficacy of Semax in the treatment of patients at different stages of ischemic stroke
Influence of the N-terminus acetylation of Semax, a synthetic analog of ACTH(4-10), on copper(II) and zinc(II) coordination and biological properties
Semax, an ACTH4-10 peptide analog with high affinity for copper(II) ion and protective ability against metal induced cell toxicity
Comparison of the temporary dynamics of NGF and BDNF gene expression in rat hippocampus, frontal cortex, and retina under Semax action
Semax and Pro-Gly-Pro activate the transcription of neurotrophins and their receptor genes after cerebral ischemia
Neurotrophin gene expression in rat brain under the action of Semax, an analogue of ACTH 4-10
Semax, an analogue of adrenocorticotropin (4-10), is a potential agent for the treatment of attention-deficit hyperactivity disorder and Rett syndrome
Semax, an ACTH(4-10) analogue with nootropic properties, activates dopaminergic and serotoninergic brain systems in rodents
The heptapeptide SEMAX stimulates BDNF expression in different areas of the rat brain in vivo
Quick Facts
- Class
- Nootropic Peptide
- Tier
- F
- Evidence
- Limited
- Safety
- Limited Data
- Updated
- Mar 2026
- Citations
- 18PubMed
Also known as
Tags
Related Goals
Conditions Discussed
Evidence Score
Clinical Trials
View Clinical TrialsLinks to ClinicalTrials.gov for reference. Listing does not imply endorsement.